<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144431" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prostate Cancer Tissue-Based Biomarkers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>R I</surname>
            <given-names>Anu</given-names>
          </name>
          <aff>MVR Cancer Centre and Research Institute</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shamsudeen</surname>
            <given-names>Shafeek</given-names>
          </name>
          <aff>MVR Cancer Centre &#x00026; Research Institute</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anu R I declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shafeek Shamsudeen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144431.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Prostate cancer is the fourth most commonly diagnosed cancer worldwide, with approximately 1.4 million new cases, and is more commonly diagnosed in developed countries. To combat the disease, advanced biomarkers are constantly in development. Even though patients with prostate cancer have improved overall survival, from a global perspective, this is a disease that requires attention in terms of better diagnostic and treatment modalities, especially in the metastatic setting. This activity describes tissue-based biomarkers useful in clinical practice to help determine risk stratification at critical decision points in prostate cancer, which will help determine the relative need for a re-biopsy or further intervention, thus aiding physicians and patients in personalizing care for their disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiopathology of prostate cancer.</p></list-item><list-item><p>Review the risk factors identified as causal factors in prostate cancer worldwide.</p></list-item><list-item><p>Identify the indications and utility of the new prostate cancer biomarker tests in patients with prostate cancer.</p></list-item><list-item><p>Summarize the utility of a broad panel of next-generation sequencing tests in resected prostate cancer tissue in the metastatic setting.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144431&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144431">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-144431.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Prostate cancer is the malignancy arising from the prostate gland in men. Cancer of the prostate is the fourth most common malignancy worldwide amongst both sexes and is the fifth leading cause of death in men, according to the 2020 census. It is also a malignancy related to a nation&#x02019;s development index, like breast, lung, and colorectum cancers.<xref ref-type="bibr" rid="article-144431.r1">[1]</xref></p>
        <p>The cumulative incidence and mortality risk are higher in countries with very high Human Development Index (HDI) scores (7.88%) as opposed to those nations with low HDI (3.29%) scores.&#x000a0;</p>
        <p>In general, the incidence and mortality of prostate cancer are lowest in Asia and highest in the Caribbean and Africa.&#x000a0;Western Europe, Australia, and North America have relatively high incidence rates but low mortality.<xref ref-type="bibr" rid="article-144431.r1">[1]</xref>&#x000a0;</p>
        <p>Even though patients with prostate cancer have improved overall survival, from a global perspective, this is a disease that requires attention in terms of better diagnostic and treatment modalities, especially in the metastatic setting. Properly used prostate cancer tissue-based biomarkers can significantly improve prognostic determinations, risk stratification, and treatment selection.</p>
        <p>Until recently, prostate cancer diagnosis and risk stratification has been based solely on clinical stage, grade group/Gleason score, and prostate-specific antigen (PSA) levels. The tumor being highly heterogenous, Gleason scoring adopts a sum of scores from two different histological areas. Clinicians use these variables to construct nomograms and risk calculators. The most commonly used prognostic tools are the Partin tables (to predict tumor and nodal stage after radical prostatectomy), the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram&#x000a0;(predicts postoperative progression-free survival in addition to the tumor and nodal stage after radical prostatectomy), and the Cancer of the Prostate Risk Assessment (CAPRA) score&#x000a0;(to predict postoperative high-risk features, lymph node involvement and recurrence-free survival at 3 and 5 years).<xref ref-type="bibr" rid="article-144431.r2">[2]</xref><xref ref-type="bibr" rid="article-144431.r3">[3]</xref>&#x000a0;Additional tools are the Briganti nomogram&#x000a0;and the Kattan nomogram.<xref ref-type="bibr" rid="article-144431.r2">[2]</xref><xref ref-type="bibr" rid="article-144431.r4">[4]</xref></p>
        <p>Taken together, these clinicopathological variables and prognostic tools,&#x000a0;though somewhat useful in real-world clinical situations, are inadequate to reliably predict the course of the disease as evidenced by real-world experience. Worse, they are rapidly becoming obsolete as the field of oncology is being catapulted by cutting-edge molecular diagnostics revolving around cancer genomics, transcriptomics, biomarkers, and epigenomics.</p>
        <p>This article addresses the utility and clinical application of new and cutting-edge prostate cancer tissue-based biomarker assays that have either been approved by regulatory bodies&#x000a0;or&#x000a0;are in a developmental pipeline awaiting further research.</p>
      </sec>
      <sec id="article-144431.s3" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>While the exact cause of prostate cancer is unknown, variations in the DNA leading to mutations or aberrant gene fusions could be the initiating event. However, there are strong risk factors that facilitate the development of malignancy. Older age, western African ancestry, family history of prostate cancer, especially with segregation of <italic toggle="yes">BRCA1 and BRCA2 </italic>gene variations, Lynch syndrome, obesity, unhealthy diet style, inadequate beta-carotene, alcohol consumption, smoking, and specific medications&#x000a0;are known risk factors with increasing evidence of their contributions to the underlying etiology.<xref ref-type="bibr" rid="article-144431.r5">[5]</xref><xref ref-type="bibr" rid="article-144431.r6">[6]</xref><xref ref-type="bibr" rid="article-144431.r7">[7]</xref><xref ref-type="bibr" rid="article-144431.r8">[8]</xref></p>
        <p>
<bold>Epidemiology</bold>
</p>
        <p>Most men with prostate cancer will not die from the disease. In the United States, the 5-year overall survival rate is 99%.<xref ref-type="bibr" rid="article-144431.r9">[9]</xref>&#x000a0;The American Cancer Society has estimated that it will still kill 34,500 men out of 268,500 newly reported cases in the US in 2022.<xref ref-type="bibr" rid="article-144431.r10">[10]</xref></p>
        <p>Prostate cancer is more common in developed countries than in the Third World.<xref ref-type="bibr" rid="article-144431.r11">[11]</xref>&#x000a0;The National Cancer Institute (NCI) has reported that the lifetime risk of acquiring clinically significant prostate cancer (Gleason 4 disease) in the US is 11.6%.<xref ref-type="bibr" rid="article-144431.r10">[10]</xref></p>
        <p>In 60% of countries worldwide (112/185), prostate cancer is the most commonly diagnosed malignancy.<xref ref-type="bibr" rid="article-144431.r12">[12]</xref>&#x000a0;Statistically, 7.3% of the total number of new cancer cases and 3.8% of the total number of deaths in 2020 were attributed to prostate cancer, as per GLOBOCAN 2020 data.<xref ref-type="bibr" rid="article-144431.r13">[13]</xref>&#x000a0;Worldwide incidence in 2020 was reported as 1,414,000 new cancer cases and 375,304 deaths.<xref ref-type="bibr" rid="article-144431.r14">[14]</xref></p>
        <p>The worldwide incidence of prostate cancer is 30.7 per 100,000, and the global mortality rate is 7.7 per 100,000.</p>
        <p>According to the World Cancer Research Fund International, the nations with the highest per capita incidence and mortality rates of prostate cancer are:&#x000a0;</p>
        <p>Countries with the Highest Prostate Cancer Incidence per 100,000:</p>
        <list list-type="order">
          <list-item>
            <p>Guadaloupe (184)</p>
          </list-item>
          <list-item>
            <p>Martinique (168)</p>
          </list-item>
          <list-item>
            <p>Ireland (111)</p>
          </list-item>
          <list-item>
            <p>Barbados (110)</p>
          </list-item>
          <list-item>
            <p>St. Lucia (103)</p>
          </list-item>
          <list-item>
            <p>Estonia (102)</p>
          </list-item>
          <list-item>
            <p>Puerto Rico (101)</p>
          </list-item>
          <list-item>
            <p>France (100)</p>
          </list-item>
          <list-item>
            <p>Sweden (99)</p>
          </list-item>
          <list-item>
            <p>Bahamas (98)</p>
          </list-item>
        </list>
        <p>Countries with the Highest Prostate Cancer Mortality Rate per 100,000:</p>
        <list list-type="order">
          <list-item>
            <p>Zimbabwe (42)</p>
          </list-item>
          <list-item>
            <p>Barbados (40.3)</p>
          </list-item>
          <list-item>
            <p>Haiti (40.2)</p>
          </list-item>
          <list-item>
            <p>Zambia (40.1)</p>
          </list-item>
          <list-item>
            <p>Jamaica (39.4)</p>
          </list-item>
          <list-item>
            <p>Trinidad and Tobago&#x000a0; (38.9)</p>
          </list-item>
          <list-item>
            <p>Bahamas (36)</p>
          </list-item>
          <list-item>
            <p>Dominican Republic (35)</p>
          </list-item>
          <list-item>
            <p>St. Lucia (33)</p>
          </list-item>
          <list-item>
            <p>Ivory Coast (30)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144431.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The prostate gland is located at the base of the penis in the pelvis.&#x000a0;From a lateral, anatomic view, it is adjacent and anterior to the rectum as well as inferior to the urinary bladder.</p>
        <p>The tissue is predominantly glandular, producing an alkaline secretion that constitutes about 25 to 30% of the seminal fluid.</p>
        <p>Malignancy arising from the gland is classified as an adenocarcinoma. The commonest metastatic sites are the draining regional lymph nodes and the bony skeleton.<xref ref-type="bibr" rid="article-144431.r10">[10]</xref>&#x000a0;Chronic inflammation is also believed to be a facilitator of prostatic malignant transformation and neoplastic development.<xref ref-type="bibr" rid="article-144431.r15">[15]</xref><xref ref-type="bibr" rid="article-144431.r16">[16]</xref> Malignancy is thought to arise from mutations within basal&#x000a0;or luminal cells.<xref ref-type="bibr" rid="article-144431.r17">[17]</xref><xref ref-type="bibr" rid="article-144431.r18">[18]</xref>&#x000a0;</p>
        <p>The stages of malignant neoplasia are well-studied. It begins with prostatic intraepithelial neoplasia (PIN) and/or atypical small acinar proliferation (ASAP), progresses to localized malignancy, then to advanced cancer with local invasion, and finally to florid metastatic disease.<xref ref-type="bibr" rid="article-144431.r19">[19]</xref></p>
        <p>The genome and epigenome play a crucial role in the initiation and progression of prostatic malignancy. Genome-wide association studies (GWAS) have shown that about 31.5% of the familial relative risk (FRR) is attributed to 167 common variants or susceptible loci in the genome, and approximately 6% are due to <italic toggle="yes">BRCA2 </italic>and <italic toggle="yes">HOXB13</italic>. The first GWAS (2006) found single nucleotide polymorphisms (SNPs) in the 8q24 loci, which are believed to influence the oncogene <italic toggle="yes">MYC</italic>.</p>
        <p>Besides <italic toggle="yes">HOXB13 </italic>and <italic toggle="yes">BRCA2</italic>, familial mutations have also been found in <italic toggle="yes">ATM</italic>,&#x000a0;<italic toggle="yes">CHEK2</italic>,&#x000a0;<italic toggle="yes">BRCA1</italic>,&#x000a0;<italic toggle="yes">RAD51D</italic>, and&#x000a0;<italic toggle="yes">PALB2 </italic>genes.<xref ref-type="bibr" rid="article-144431.r20">[20]</xref></p>
        <p>As for common somatic variants found in prostatic cancer, the following are implicated:<xref ref-type="bibr" rid="article-144431.r21">[21]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Deletions in <italic toggle="yes">APC, CHD1, ETS2, NKX3.1,</italic>&#x000a0;and SETD2.</p>
          </list-item>
          <list-item>
            <p>Deletions/mutations in <italic toggle="yes">ATM, BRCA1, BRCA2, ERF, KMT2A, KMT2C, KMT2D, KDM1A, KDM3A, KDM6A, NCOR1, NCOR2, PTEN, RB1, SMAD4, SMARCA1, SMARCB1, </italic>and<italic toggle="yes"> TP53.</italic></p>
          </list-item>
          <list-item>
            <p>Amplification/mutation/splice variant mutations in <italic toggle="yes">AR.</italic></p>
          </list-item>
          <list-item>
            <p>Fusion/deletion in <italic toggle="yes">ERG </italic>and<italic toggle="yes">&#x000a0;</italic>ETVs.</p>
          </list-item>
          <list-item>
            <p>Mutations in <italic toggle="yes">EZH2, FOXA1, IDH1, </italic>and<italic toggle="yes"> SPOP.</italic></p>
          </list-item>
          <list-item>
            <p>Amplification in <italic toggle="yes">MYC, MYCN, </italic>and<italic toggle="yes"> SETDB1</italic>.</p>
          </list-item>
        </list>
        <p>The E26 transformation-specific (ETS) family of transcription factors is particularly important in prostate cancer, as <italic toggle="yes">TMPRSS2-ERG </italic>fusion is seen in ~50% of localized malignancies.<xref ref-type="bibr" rid="article-144431.r22">[22]</xref>&#x000a0;(<italic toggle="yes">ERG </italic>and ETVs are members of the ETS family of transcription factors.)</p>
        <p>The molecular biology of metastatic prostate cancer is typified by novel EMT (Epithelial-Mesenchymal Transition) processes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone metastasis is supported by stromal cell-derived factor-1 (SDF-1/ CXCL12) and the CXCR4 receptor for homing and invasion of tumor cells.<xref ref-type="bibr" rid="article-144431.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hematopoietic stem cells locate and bind to niche via annexin A2 (ANXA2) that is found to be overexpressed in prostate cancer cells.<xref ref-type="bibr" rid="article-144431.r24">[24]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tumor-derived exosomes carrying integrins have been implicated in organotropic metastasis.<xref ref-type="bibr" rid="article-144431.r25">[25]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased RANK-RANKL signaling within prostate tumor cells has significantly promoted skeletal metastasis.<xref ref-type="bibr" rid="article-144431.r26">[26]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144431.s5" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <table-wrap id="article-144431.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1 Contemporary Assays and Techniques&#x000a0;</title>
          </caption>
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Sl No.</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Tissue-based assay</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Starting material</bold>
</td>
                <td rowspan="1" colspan="1">
<bold><italic toggle="yes">Omics</italic> analyzed</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Technique</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">Decipher</td>
                <td rowspan="1" colspan="1">
<p>FFPE tissue</p>
Tumor specimen of at least 0.5&#x000a0;mm</td>
                <td rowspan="1" colspan="1">Transcriptome</td>
                <td rowspan="1" colspan="1">Microarray</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">Prolaris&#x000a0;Molecular Score</td>
                <td rowspan="1" colspan="1">FFPE tissue</td>
                <td rowspan="1" colspan="1">Transcriptome</td>
                <td rowspan="1" colspan="1">Quantitative polymerase chain reaction</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1">Oncotype DX&#x000a0;Genomic Prostate Score&#x000a0;</td>
                <td rowspan="1" colspan="1">FFPE tissue</td>
                <td rowspan="1" colspan="1">Transcriptome</td>
                <td rowspan="1" colspan="1">Reverse transcriptase PCR</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">4</td>
                <td rowspan="1" colspan="1">Somatic Tumor Testing</td>
                <td rowspan="1" colspan="1">FFPE tissue</td>
                <td rowspan="1" colspan="1">Genome</td>
                <td rowspan="1" colspan="1">Next Generation Sequencing&#x000a0;&#x000a0;</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">5</td>
                <td rowspan="1" colspan="1">ConfirmMDx</td>
                <td rowspan="1" colspan="1">FFPE tissue</td>
                <td rowspan="1" colspan="1">Epigenome</td>
                <td rowspan="1" colspan="1">Epigenetic multiplex PCR&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-144431.s6" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>
<bold>Prostate Specific Antigen (PSA) Screening</bold>
</p>
        <p>There is considerable controversy regarding PSA screenings for prostate cancer. The issue is not that PSA screening does not find prostate cancer but that it leads to overdiagnosis and overtreatment of indolent cancers without clinical significance for the patient.<xref ref-type="bibr" rid="article-144431.r27">[27]</xref>&#x000a0;(This would not include men who are found to have a suspicious nodule on physical examination and would need further evaluation.)&#x000a0;</p>
        <p>There is a multitude of guidelines from a variety of professional organizations and societies regarding PSA screening. They all recommend a discussion of the risks and benefits of PSA screenings and starting testing in appropriate individuals who desire screening only after the process of shared decision-making has been completed.<xref ref-type="bibr" rid="article-144431.r27">[27]</xref></p>
        <p>There is a clear distinction between recommendations for men at average risk and those at high risk. High-risk individuals would include those men with a direct blood relative with prostate cancer (especially if it appeared at an early age or resulted in death), all those of African descent, a family history of multiple malignancies, Lynch syndrome, or known <italic toggle="yes">BRCA2</italic>&#x000a0;or similar high-risk germline carriers.<xref ref-type="bibr" rid="article-144431.r27">[27]</xref>&#x000a0;Since about 10% of all prostate cancers occur in men younger than 55 and 1% before the age of 50, it seems reasonable to recommend a baseline PSA test at age 45, at least for men with high-risk factors.<xref ref-type="bibr" rid="article-144431.r28">[28]</xref></p>
        <p>All of the guidelines recommend halting routine screenings in men with less than a 10-year life expectancy or by age 70 to 75. The average life expectancy of a generally healthy 75-year-old (according to the Social Security Actuarial Tables) is about 11 years, so the 75-year-old cutoff for routine screenings is suggested.<xref ref-type="bibr" rid="article-144431.r27">[27]</xref></p>
        <p>For a more detailed and comprehensive discussion of the PSA testing controversy, please review our companion StatPearls reference article on "Prostate Cancer Screening."</p>
        <p>Summary of Published PSA Screening Guidelines:</p>
        <list list-type="bullet">
          <list-item>
            <p>The American Cancer Society suggests starting PSA screening discussions at age 50 for men at average risk and earlier for high-risk individuals.<xref ref-type="bibr" rid="article-144431.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>The American Medical Association recommends discussing PSA screening at age 45 for high-risk men and age 50 for normal-risk individuals.</p>
          </list-item>
          <list-item>
            <p>The American Urological Association recommends initial discussions regarding screening for high-risk individuals aged 40 to 54 years and average-risk men 55 years and older.<xref ref-type="bibr" rid="article-144431.r30">[30]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The European Association of Urology (EAU) recommends starting a review of screenings at age 40 for men with known&#x000a0;<italic toggle="yes">BRCA2</italic> germline mutations, age 45 for other high-risk individuals, and age 50 for average-risk males.<xref ref-type="bibr" rid="article-144431.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>The United States Preventive Services Task Force (USPSTF) currently recommends discussing the pros and cons of PSA screening for prostate cancer with men aged 55 to 69.<xref ref-type="bibr" rid="article-144431.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Tissue-Based Biomarkers</bold>
</p>
        <p>All of these biomarker tests are intended to help in the decision-making process for patients with a predicted life expectancy of at least ten years and where the results are likely to make a difference in their final treatment selection.<xref ref-type="bibr" rid="article-144431.r31">[31]</xref>&#x000a0;(A description and definition of the various prostate cancer risk groups can be found in our companion StatPearls reference article on "Prostate Cancer.")<xref ref-type="bibr" rid="article-144431.r10">[10]</xref></p>
        <p>Of the multitude of assays that have been developed, the most valuable are ConfirmMDx, Decipher, Oncotype DX, Prolaris, ProMark, and Somatic tumor testing for targeted therapy.<xref ref-type="bibr" rid="article-144431.r32">[32]</xref></p>
        <p><bold>ConfirmMDx,</bold> developed by MDxHealth, Inc. in Irvine, California, is a tissue-based assay used to predict the incidence of finding malignancy on a repeat biopsy for patients whose initial histology was negative. It reports the likelihood of finding cancer as a percentage.<xref ref-type="bibr" rid="article-144431.r33">[33]</xref>&#x000a0;The assay technically employs the epigenetic multiplex polymerase chain reaction (PCR) method to assess promoter methylation of 3 genes&#x000a0;<italic toggle="yes">RASSF1</italic>,&#x000a0;<italic toggle="yes">GSTP1,</italic>&#x000a0;and&#x000a0;<italic toggle="yes">APC,&#x000a0;</italic>in the biopsy specimen. The concept is based on epigenomic changes that are presumably found in tumor-adjacent normal tissue. The Methylation Analysis to Locate Occult Cancer (MATLOC) and the Detection of Cancer Using Methylated Events in Negative Tissue (DOCUMENT) studies have validated the assay.<xref ref-type="bibr" rid="article-144431.r34">[34]</xref>&#x000a0;</p>
        <p>The latter found a negative predictive value (NPV) of 90%, and another study found an NPV of 96% in patients with lower methylation levels.<xref ref-type="bibr" rid="article-144431.r35">[35]</xref>&#x000a0;Stewart GD et al. found a 64% reduction of prostate biopsies with ConfirmMDx use.<xref ref-type="bibr" rid="article-144431.r36">[36]</xref><xref ref-type="bibr" rid="article-144431.r37">[37]</xref>&#x000a0;The MDxHealth supported Prostate Assay Specific Clinical Utility at Launch (PASCUAL) (NCT02250313) study's results of 600 participants are yet to be published.</p>
        <p>Patients who have had a negative prostate biopsy can consider using the ConfirmMDx test if they are contemplating a second biopsy. It is appropriate for patients with unexplained, persistent high, or rising PSA levels. It can also be useful in patients with high-risk factors or even just heightened anxiety about their biopsy results, such as multiple negative biopsies.</p>
        <p><bold>The Decipher Prostate Genomic Classifier</bold> is useful in two clinical scenarios: for men with localized prostate cancer deciding between active surveillance vs. intervention and in patients with high-risk pathology or clinical features after radical prostatectomy to decide on treatment or observation. The assay gives a result as a Genomic Classifier (GC) score of 0-1.0 (also known as the Decipher Biopsy score or Decipher Radical Prostatectomy score). The clinical endpoints targeted are the 5-year risk of metastasis, the likelihood of high-grade cancer on radical prostatectomy, and the 10-year prostate cancer-specific mortality risk.<xref ref-type="bibr" rid="article-144431.r38">[38]</xref><xref ref-type="bibr" rid="article-144431.r39">[39]</xref><xref ref-type="bibr" rid="article-144431.r40">[40]</xref>&#x000a0;A Genomic Classifier score of 0 to 0.45 is considered low risk, 0.46 to 0.6 is&#x000a0;considered&#x000a0;average risk, and above 0.61 is high risk.</p>
        <p>The National Comprehensive Cancer Network (NCCN) guidelines suggest that the assay could be offered to patients with very low, low, and intermediate risk on biopsy, with a life expectancy of a minimum of 10 years. It can also be offered to patients with pathological T2 disease and positive surgical margins, persistent or recurrent PSA levels after radical prostatectomy, or pathological T3 disease to help decide on adjuvant radiation therapy.&#x000a0;</p>
        <p>Technically, the Decipher test is a transcriptomic assay that uses the microarray method to study the expression of 22 genes, namely, <italic toggle="yes">LASP1, IQGAP3, NFIB, S1PR4, THBS2, ANO7, PCDH7, MYBPC1, EPPK1, TSBP, PBX1, NUSAP1, ZWILCH, UBE2C, CAMK2N1, RABGAP1, PCAT-32, GLYATL1P4, PCAT-80, </italic>and<italic toggle="yes"> TNFRSF19.&#x000a0;</italic>These genes play an important role in the cell cycle, cell growth, differentiation, and androgen receptor signaling. The assay was developed by comparing 192 RP samples from men with metastatic prostate cancer and 353 healthy controls. The initial validation produced an area-under-curve (AUC) of 0.90.<xref ref-type="bibr" rid="article-144431.r41">[41]</xref>&#x000a0;The Decipher biopsy test's score to predict metastasis has been validated with an AUC of 0.8.<xref ref-type="bibr" rid="article-144431.r42">[42]</xref>&#x000a0;</p>
        <p>A systematic review of 42 studies using data from 30,407 patients was conducted by Jairath K et al. to analyze the utility of Decipher in clinical decision-making.<xref ref-type="bibr" rid="article-144431.r43">[43]</xref> The group concluded that Decipher GC scores were significant and useful in intermediate-risk cancer and post-prostatectomy cases where they contributed to a change in management.<xref ref-type="bibr" rid="article-144431.r43">[43]</xref> There are currently at least 19 ongoing clinical trials studying the utility of this assay in prostate cancer.<xref ref-type="bibr" rid="article-144431.r43">[43]</xref></p>
        <p><bold>The Oncotype DX&#x000a0;Genomic Prostate Score</bold>&#x000a0;was developed following similar commercial assays for breast and colorectal cancer. This assay is suitable for men with very low and low-risk prostate cancer. The assay offers results as a Genomic Prostate Score (GPS) of 0-100. The resulting score displays the likelihood of Gleason Grade Group 1 or 2 after radical prostatectomy or the likelihood of organ-confined disease after definitive surgery.<xref ref-type="bibr" rid="article-144431.r44">[44]</xref><xref ref-type="bibr" rid="article-144431.r45">[45]</xref>&#x000a0;It is, therefore, most appropriate for very low-risk and low-risk disease.</p>
        <p>The assay uses reverse transcriptase PCR to study the expression of 12 genes involved in cell proliferation, organization, stromal response, androgen receptor pathway, and five housekeeping genes.&#x000a0;<italic toggle="yes">TPX2, FLNC, GSN, TPM2, GSTM2, BGN, COL1A1, SFRP4, AZGP1, KLK2, SRD5A2,&#x000a0;</italic>and<italic toggle="yes">&#x000a0;FAM13C</italic>&#x000a0;are the genes measured for expression. Oncotype DX has been validated in various cohorts.<xref ref-type="bibr" rid="article-144431.r46">[46]</xref><xref ref-type="bibr" rid="article-144431.r47">[47]</xref></p>
        <p><bold>The ProMark test</bold>&#x000a0;was intended for patients with a Gleason grade group (GGG) score of 1 or 2 on biopsy (Gleason 3+3=6 and 3+4=7), which generally represents very low, low, and favorable intermediate-risk disease. The clinical endpoint predicted is the risk of Gleason grade group &#x02265;3, or non-organ confined cancer after radical prostatectomy. Results are depicted as a score of 0&#x000a0;to 1.<xref ref-type="bibr" rid="article-144431.r48">[48]</xref><xref ref-type="bibr" rid="article-144431.r49">[49]</xref>&#x000a0;</p>
        <p>The test uses measurements of eight proteins involved in cell proliferation, signaling, and stress response, namely <italic toggle="yes">DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, pS6, </italic>and<italic toggle="yes"> YBOX1</italic>.<xref ref-type="bibr" rid="article-144431.r50">[50]</xref>&#x000a0;The assay predicts disease aggressiveness to help decide for or against active surveillance in favor of definitive therapy.&#x000a0;</p>
        <p>Validation of the ProMark test showed:<xref ref-type="bibr" rid="article-144431.r49">[49]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The positive predictive value (PPV) for detecting favorable disease with a risk score &#x02264;0.33 is 83.6% with a specificity of 90%.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The positive predictive value (PPV) for identifying unfavorable disease with a risk score &#x0003e;0.80 is 76.9%.</p>
          </list-item>
        </list>
        <p>A clinical trial on the "Effects of a new diagnostic test on the care of prostate cancer patients: The ProMark clinical utility study" (NCT04550416) was completed in 2020, but the results have not yet been reported.</p>
        <p><bold>The Prolaris prostate&#x000a0;cancer prognostic test</bold> is used in two clinical scenarios: newly diagnosed patients with prostate cancer (Prolaris biopsy test) and after radical prostatectomy (Prolaris post-prostatectomy test). Results are given as Cell Cycle Progression (CCP) scores of 0&#x000a0;to 6. The clinical endpoint is the 10-year risk of prostate cancer-specific mortality as well as the 10-year risk of biochemical recurrence (BCR) after radical prostatectomy.<xref ref-type="bibr" rid="article-144431.r51">[51]</xref><xref ref-type="bibr" rid="article-144431.r52">[52]</xref><xref ref-type="bibr" rid="article-144431.r53">[53]</xref>&#x000a0;</p>
        <p>The NCCN recommends the Prolaris assay for virtually all biopsy-proven prostate cancer patients (very low, low, favorable, and unfavorable intermediate-risk and high-risk) with a minimum life expectancy of 10 years. It can also be used post-prostatectomy. These indications were recently expanded.</p>
        <p>Prolaris is a transcriptomic assay utilizing quantitative polymerase chain reaction (PCR) testing to measure the gene expression of 31 cell cycle progression genes against 15 housekeeping genes. The assay has been validated extensively yet is being clinically used relatively sparingly to help decide on active surveillance or definitive intervention (surgery/radiation) in borderline lower-risk prostate cancers.</p>
        <p><bold>Somatic Tumor Testing</bold> is generally performed on patients with metastatic castration-resistant prostate cancer who have progressed on androgen receptor-directed therapy, irrespective of any prior treatment with docetaxel.<xref ref-type="bibr" rid="article-144431.r54">[54]</xref>&#x000a0;It may also be considered in patients with regional or castration-na&#x000cf;ve sensitive metastatic prostate cancer.</p>
        <p>Multigene molecular testing for patients with low, intermediate, and high-risk prostate cancer who enjoy an estimated life expectancy &#x02265;10 years is suggested by the NCCN expert committee. The most recent NCCN guidelines recommend tumor genetic testing for homologous recombination repair mutations, microsatellite instability-high (MSI-H), deficient mismatch repair (dMMR) genes, and tumor mutational burden in patients with metastatic castration-resistant prostate cancer (mCRPC).&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Homologous recombination repair (HRR) genes: The HRR pathway is a metabolic process that aids the homology-mediated repair of damaged DNA.<xref ref-type="bibr" rid="article-144431.r55">[55]</xref>&#x000a0;The genes included in the testing panel for metastatic prostate cancer, as suggested by the NCCN expert committee, are&#x000a0;<italic toggle="yes">BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, </italic>and<italic toggle="yes"> RAD54L.&#x000a0;</italic>It may be suitable for a PARP inhibitor. (see below)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Microsatellite instability (MSI): Microsatellites are short stretches of repetitive nucleic bases. During replication, slippage errors may occur, leading to microsatellite (MSI) and genomic instability. Microsatellite instability is categorized as low, stable, or high. Clinically, the former two states (Low, Stable) are similar.<xref ref-type="bibr" rid="article-144431.r56">[56]</xref>&#x000a0;Polymerase chain reaction testing uses Bethesda pentaplex panel to assess microsatellite instability, while Next-Generation Sequencing (NGS) analyzes MSI status over a larger area of the genome.<xref ref-type="bibr" rid="article-144431.r57">[57]</xref>&#x000a0;(Next-generation sequencing, or NGS, uses parallel sequencing of multiple small DNA fragments for genomic analysis.)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mismatch repair (MMR) genes: DNA Mismatch repair is a biological process that identifies and rectifies base mismatch, insertion, or deletion mispairs that may occur during DNA replication or recombination.<xref ref-type="bibr" rid="article-144431.r58">[58]</xref>&#x000a0;The key players of the MMR pathway are <italic toggle="yes">MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, </italic>and<italic toggle="yes"> PMS2,&#x000a0;</italic>in addition to significant proteins including ExoI, Pol&#x000a0;&#x003b4;, PCNA, RPA, HMGB1, RFC, and DNA Ligase I.<xref ref-type="bibr" rid="article-144431.r58">[58]</xref>&#x000a0;Qualitative functional analysis of MMR genes is measured by immunohistochemistry or by an indirect estimation of intact function assessed by MSI testing using PCR or NGS techniques. The result could be expressed as a deficient or proficient expression.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumor mutation burden (TMB): From a biological perspective, the Tumor Mutation Burden (TMB) is the total number of mutations present in the DNA of a cancer cell. This is determined by calculating the number of mutations per megabase of the genomic sequence examined.<xref ref-type="bibr" rid="article-144431.r59">[59]</xref>&#x000a0;It is calculated&#x000a0;during the post-processing step of the NGS assay.<xref ref-type="bibr" rid="article-144431.r60">[60]</xref>&#x000a0;A high tumor mutation burden (TMB-H) indicates cancer that may respond to immunotherapy.&#x000a0;</p>
          </list-item>
        </list>
        <p>A finding of high microsatellite instability (MSI-H), deficient mismatch repair genes (dMMR), or high tumor mutation burden (TMB &#x02265;10 mut/Mb) is an indicator for the addition of pembrolizumab, an immune checkpoint inhibitor, in appropriate clinical settings.<xref ref-type="bibr" rid="article-144431.r61">[61]</xref>&#x000a0;</p>
        <p><bold>PARP inhibitors</bold> block the activity of the enzyme polyadenosine diphosphate-ribose polymerase (PARP), which would normally act to repair damaged intracellular DNA. They can effectively treat castration-resistant prostate cancers with HRR (BRCA) mutations. Olaparib and rucaparib are two examples.</p>
        <list list-type="bullet">
          <list-item>
            <p>Olaparib can be used in metastatic castration-resistant prostate cancer and BRCA or other DNA damage repair gene mutations where the malignancy has progressed.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Rucaparib may also be used in metastatic castration-resistant prostate cancer patients who test positive for BRCA mutations and have previously been treated with&#x000a0;androgen receptor blockers and taxane-based chemotherapy.</p>
          </list-item>
          <list-item>
            <p>The FoundationOne CDx is a tissue-based molecular assay approved by the FDA for metastatic castrate-resistant prostate as a companion diagnostic for Olaparib, the biomarker being a panel of the homologous recombination repair (HRR) genes.</p>
          </list-item>
        </list>
        <p><bold>Androgen Receptor Splice Variant 7 (AR-V7</bold>) has been associated with more aggressive disease, shorter progression to metastatic cancer, higher PSA levels, greater disease burden, and shorter overall survival in metastatic prostate cancer patients.<xref ref-type="bibr" rid="article-144431.r62">[62]</xref><xref ref-type="bibr" rid="article-144431.r63">[63]</xref>&#x000a0;AV-V7 status may also work as a prognostic marker in metastatic disease, suggesting resistance to abiraterone and enzalutamide but not taxanes.<xref ref-type="bibr" rid="article-144431.r64">[64]</xref><xref ref-type="bibr" rid="article-144431.r65">[65]</xref>&#x000a0;</p>
        <p>Niclosamide and TAS3681 have been specifically designed to target and inhibit AR-V7, but their clinical use is still being investigated.<xref ref-type="bibr" rid="article-144431.r63">[63]</xref>&#x000a0;The NCCN expert committee recommends AV-V7 testing in circulating tumor cells (CTCs) to help decide on a therapeutic choice post-abiraterone or enzalutamide for metastatic castration-resistant prostate cancer.</p>
        <p>
<bold>Future and Investigational Biomarkers</bold>
</p>
        <p>Newer potential biomarkers are being studied and developed, such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Androgen receptor splice variant 7 (AR-V7) testing using liquid biopsy techniques&#x000a0;<xref ref-type="bibr" rid="article-144431.r66">[66]</xref><xref ref-type="bibr" rid="article-144431.r67">[67]</xref></p>
          </list-item>
          <list-item>
            <p>PD-1/PD-L1 testing&#x000a0;<xref ref-type="bibr" rid="article-144431.r68">[68]</xref></p>
          </list-item>
          <list-item>
            <p>CD276 testing&#x000a0;<xref ref-type="bibr" rid="article-144431.r69">[69]</xref></p>
          </list-item>
          <list-item>
            <p>CD73 testing&#x000a0;<xref ref-type="bibr" rid="article-144431.r70">[70]</xref></p>
          </list-item>
          <list-item>
            <p>Tumor-associated macrophages (TAMs)&#x000a0;<xref ref-type="bibr" rid="article-144431.r71">[71]</xref></p>
          </list-item>
          <list-item>
            <p>Cytotoxic CD8 tumor-infiltrating lymphocytes (TILs)&#x000a0;<xref ref-type="bibr" rid="article-144431.r72">[72]</xref></p>
          </list-item>
          <list-item>
            <p>Regulatory T cells (Tregs)&#x000a0;<xref ref-type="bibr" rid="article-144431.r73">[73]</xref></p>
          </list-item>
          <list-item>
            <p>Mast cell testing&#x000a0;<xref ref-type="bibr" rid="article-144431.r74">[74]</xref><xref ref-type="bibr" rid="article-144431.r75">[75]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The NCCN guidelines mention Ki-67% and <italic toggle="yes">PTEN&#x000a0;</italic>assessment&#x000a0;as possible biomarkers, but they are not currently recommended.&#x000a0;</p>
        <p>The PTEN/TMPRSS2-ERG test developed by Metamark was designed for patients with a Gleason grade group score of 1 or 2 on biopsy. The assay checks for deletion of <italic toggle="yes">PTEN </italic>and fusion of <italic toggle="yes">TMPRSS2-ERG.</italic><xref ref-type="bibr" rid="article-144431.r76">[76]</xref>&#x000a0;Loss of <italic toggle="yes">PTEN</italic> function is associated with poorer outcomes, and the presence of <italic toggle="yes">TMPRSS2-ERG </italic>fusion predicts an increased risk of metastasis. The role of these assays in aiding clinical decisions is limited today, and the NCCN expert committee does not currently recommend them.&#x000a0;</p>
        <p>A study by Thomas Dillinger et al. found seven genes&#x000a0;(<italic toggle="yes">SERPINB1</italic>,&#x000a0;<italic toggle="yes">ACSS3</italic>,&#x000a0;<italic toggle="yes">SCGB3A1, NKX2-6, HOXA7, CRABP2,</italic>&#x000a0;and&#x000a0;<italic toggle="yes">DHRS4L2)</italic>&#x000a0;were hypermethylated in malignant tumor samples compared to normal adjacent tissue.<xref ref-type="bibr" rid="article-144431.r77">[77]</xref></p>
        <p>Recent research shows that circular RNAs and linear transcripts could be useful as biomarkers for prostate cancer.</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination of circ<italic toggle="yes">ATXN10</italic>&#x000a0;and lin<italic toggle="yes">STIL</italic>&#x000a0;could be a useful biomarker to distinguish normal from malignant prostate cells.<xref ref-type="bibr" rid="article-144431.r78">[78]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The biochemical recurrence rate could be predicted by lin<italic toggle="yes">GUCY1A2</italic>, lin<italic toggle="yes">NEAT1</italic>, and lin<italic toggle="yes">STIL.&#x000a0;</italic>The method used is RT-qPCR on flash-frozen fresh tumor samples.<xref ref-type="bibr" rid="article-144431.r78">[78]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Concise Clinical Summary of Prostatic Tissue Biomarkers:</bold>
</p>
        <p>Prostate cancer tissue-based biomarkers are only useful and recommended for patients with a predicted 10-year or more life expectancy who are at a critical decision point in management. The test results are likely to make a significant difference in treatment selection.</p>
        <p>A detailed description and review of the prostate cancer risk groups can be found in our companion StatPearls reference article on "Prostate Cancer."&#x000a0;<xref ref-type="bibr" rid="article-144431.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Negative biopsy: ConfirmMDx</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Very low-risk disease: Oncotype DX, Prolaris, or ProMark</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Low-risk disease: Decipher, Oncotype DX, Prolaris, or ProMark</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Favorable intermediate-Risk Disease: Decipher, ProMark, or Prolaris</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Unfavorable intermediate-risk and high-risk disease: Decipher or Prolaris</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metastatic disease: Somatic tumor testing</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>PSA persistence or recurrence after prostatectomy: Decipher or Prolaris</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144431.s7" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>All clinically relevant tissue-based biomarkers use FFPE tissue retrieved from a surgical specimen or biopsy as starting material. Fresh frozen tissue is known to be superior for extracting nucleic acids and downstream molecular analysis, but there are practical hurdles in relying on the latter for routine clinical use.<xref ref-type="bibr" rid="article-144431.r79">[79]</xref>&#x000a0;</p>
        <p>Irrespective of the starting material for testing, it is mandatory to adhere to all necessary and recommended quality control protocols regarding specimen preparation, storage, and transport for these molecular assays to provide reliable results.</p>
      </sec>
      <sec id="article-144431.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Even though patients with prostate cancer have improved overall survival, from a global perspective, this is a disease that requires attention in terms of better diagnostic and treatment modalities, especially at critical decision points and in the metastatic setting. Properly used prostate cancer tissue-based biomarkers can significantly improve prognostic determinations, risk stratification, and treatment selection.</p>
      </sec>
      <sec id="article-144431.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Oncology practice is&#x000a0;entering a new age of improved diagnostic testing based on cancer-specific proteins, germline mutations, and genetics. The field is expanding so rapidly that it is difficult for healthcare professionals to keep up. Using the proper testing for the right patient at the right time for the right reason requires an interprofessional team approach, including primary care clinicians (MDs, DOs, NPs, and PAs), urologists, oncologists, genetic counselors, pathologists, cancer coordinators, nursing personnel, and pharmacists working together and communicating effectively to provide optimal advice, counseling, and treatment for their patients.&#x000a0;</p>
        <p>The biomarkers can provide significant insight into potential cancers. All practitioners on the case must document their findings and communicate them to the rest of the team so that all caregivers have the same accurate and updated case information from which to make decisions. Nurses will help coordinate referrals and communication between specialties, and in such cases, an oncology-specialized nurse may prove beneficial. This interprofessional paradigm in using these biomarkers will result in improved diagnosis, which will translate into better care and presumably improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-144431.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144431&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144431">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144431/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144431">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144431.s11">
        <title>References</title>
        <ref id="article-144431.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Laversanne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2021</year>
            <month>May</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-249</page-range>
            <pub-id pub-id-type="pmid">33538338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Barros</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Remmers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luiting</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>van Leenders</surname>
                <given-names>GJLH</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bekers</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Delprado</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>van der Poel</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection.</article-title>
            <source>Urology</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>168</volume>
            <fpage>156</fpage>
            <page-range>156-164</page-range>
            <pub-id pub-id-type="pmid">35803346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nason</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>MacMahon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Considine</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer.</article-title>
            <source>Ir J Med Sci</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>187</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-37</page-range>
            <pub-id pub-id-type="pmid">28478609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ondracek</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Murekeyisoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>1395</fpage>
            <page-range>1395-1401</page-range>
            <pub-id pub-id-type="pmid">27799510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rasp</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hristov</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prostate Cancer in Seniors: Part 1: Epidemiology, Pathology, and Screening.</article-title>
            <source>Fed Pract</source>
            <year>2015</year>
            <month>May</month>
            <volume>32</volume>
            <issue>Suppl 4</issue>
            <fpage>41S</fpage>
            <page-range>41S-44S</page-range>
            <pub-id pub-id-type="pmid">30766120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirchhoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balistreri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zelefsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Eastham</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Offit</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>2115</fpage>
            <page-range>2115-21</page-range>
            <pub-id pub-id-type="pmid">20215531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Germline genetics of prostate cancer.</article-title>
            <source>Prostate</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>82 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S3</fpage>
            <page-range>S3-S12</page-range>
            <pub-id pub-id-type="pmid">35657157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baena Ruiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salinas Hern&#x000e1;ndez</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cancer chemoprevention by dietary phytochemicals: Epidemiological evidence.</article-title>
            <source>Maturitas</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>94</volume>
            <fpage>13</fpage>
            <page-range>13-19</page-range>
            <pub-id pub-id-type="pmid">27823732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Dec</month>
            <day>15</day>
            <volume>123 Suppl 24</volume>
            <issue>Suppl 24</issue>
            <fpage>5160</fpage>
            <page-range>5160-5177</page-range>
            <pub-id pub-id-type="pmid">29205313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Soon-Sutton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>R I</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Skelton</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29261872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taitt</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location.</article-title>
            <source>Am J Mens Health</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1807</fpage>
            <page-range>1807-1823</page-range>
            <pub-id pub-id-type="pmid">30203706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Grossman</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Bibbins-Domingo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Doubeni</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ebell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epling</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Krist</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kubik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>May</month>
            <day>08</day>
            <volume>319</volume>
            <issue>18</issue>
            <fpage>1901</fpage>
            <page-range>1901-1913</page-range>
            <pub-id pub-id-type="pmid">29801017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deo</surname>
                <given-names>SVS</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>6497</fpage>
            <page-range>6497-6500</page-range>
            <pub-id pub-id-type="pmid">35838905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019.</article-title>
            <source>Front Public Health</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>811044</fpage>
            <pub-id pub-id-type="pmid">35252092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ittmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.</article-title>
            <source>Cancer Cell</source>
            <year>2012</year>
            <month>Feb</month>
            <day>14</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-65</page-range>
            <pub-id pub-id-type="pmid">22340597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Mitrofanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergren</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Abate-Shen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cardiff</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Califano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity.</article-title>
            <source>Nat Cell Biol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-83</page-range>
            <pub-id pub-id-type="pmid">23434823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lukacs</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>ON</given-names>
              </name>
            </person-group>
            <article-title>Isolation and functional characterization of murine prostate stem cells.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2007</year>
            <month>Jan</month>
            <day>02</day>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>181</fpage>
            <page-range>181-6</page-range>
            <pub-id pub-id-type="pmid">17185413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garraway</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>ON</given-names>
              </name>
            </person-group>
            <article-title>Identification of a cell of origin for human prostate cancer.</article-title>
            <source>Science</source>
            <year>2010</year>
            <month>Jul</month>
            <day>30</day>
            <volume>329</volume>
            <issue>5991</issue>
            <fpage>568</fpage>
            <page-range>568-71</page-range>
            <pub-id pub-id-type="pmid">20671189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Abate-Shen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of prostate cancer: new prospects for old challenges.</article-title>
            <source>Genes Dev</source>
            <year>2010</year>
            <month>Sep</month>
            <day>15</day>
            <volume>24</volume>
            <issue>18</issue>
            <fpage>1967</fpage>
            <page-range>1967-2000</page-range>
            <pub-id pub-id-type="pmid">20844012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pritchard</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mateo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>De Sarkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abida</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beltran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garofalo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carreira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elemento</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lonigro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filipenko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garraway</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>AlDubayan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Beightol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nghiem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Casadei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vijai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Sawyers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Solit</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Allen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Offit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Bono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Aug</month>
            <day>04</day>
            <volume>375</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-53</page-range>
            <pub-id pub-id-type="pmid">27433846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spring</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>DePinho</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Genetics and biology of prostate cancer.</article-title>
            <source>Genes Dev</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>32</volume>
            <issue>17-18</issue>
            <fpage>1105</fpage>
            <page-range>1105-1140</page-range>
            <pub-id pub-id-type="pmid">30181359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bjartell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jenster</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>ETS gene fusions in prostate cancer: from discovery to daily clinical practice.</article-title>
            <source>Eur Urol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-86</page-range>
            <pub-id pub-id-type="pmid">19409690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taichman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Pienta</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Taichman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>McCauley</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.</article-title>
            <source>Cancer Res</source>
            <year>2002</year>
            <month>Mar</month>
            <day>15</day>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>1832</fpage>
            <page-range>1832-7</page-range>
            <pub-id pub-id-type="pmid">11912162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiozawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ziegler</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roodman</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Loberg</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Pienta</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Taichman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.</article-title>
            <source>J Cell Biochem</source>
            <year>2008</year>
            <month>Oct</month>
            <day>01</day>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>370</fpage>
            <page-range>370-80</page-range>
            <pub-id pub-id-type="pmid">18636554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoshino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costa-Silva</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesic Mark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kohsaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Giannatale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ceder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soplop</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uryu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pharmer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bojmar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ararso</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dumont-Cole</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wexler</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Narendran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sandstrom</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Labori</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kure</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Grandgenett</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hollingsworth</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Sousa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mallya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jarnagin</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fodstad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pantel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minn</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bissell</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rajasekhar</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Ghajar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Matei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peinado</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bromberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyden</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tumour exosome integrins determine organotropic metastasis.</article-title>
            <source>Nature</source>
            <year>2015</year>
            <month>Nov</month>
            <day>19</day>
            <volume>527</volume>
            <issue>7578</issue>
            <fpage>329</fpage>
            <page-range>329-35</page-range>
            <pub-id pub-id-type="pmid">26524530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Kozieradzki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Komarova</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Sarosi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Morony</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hojilla</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Komnenovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Khokha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Penninger</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Regulation of cancer cell migration and bone metastasis by RANKL.</article-title>
            <source>Nature</source>
            <year>2006</year>
            <month>Mar</month>
            <day>30</day>
            <volume>440</volume>
            <issue>7084</issue>
            <fpage>692</fpage>
            <page-range>692-6</page-range>
            <pub-id pub-id-type="pmid">16572175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer Screening</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32310541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Seay</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kusuda</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>164</volume>
            <issue>6</issue>
            <fpage>1964</fpage>
            <page-range>1964-7</page-range>
            <pub-id pub-id-type="pmid">11061892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wender</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guessous</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>DeSantis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <collab>American Cancer Society Prostate Cancer Advisory Committee</collab>
            </person-group>
            <article-title>American Cancer Society guideline for the early detection of prostate cancer: update 2010.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>70</fpage>
            <page-range>70-98</page-range>
            <pub-id pub-id-type="pmid">20200110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.</article-title>
            <source>BJU Int</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-7</page-range>
            <pub-id pub-id-type="pmid">23924423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggener</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rumble</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Crispino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cornford</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grignon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Den</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Beltran</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>13</issue>
            <fpage>1474</fpage>
            <page-range>1474-1494</page-range>
            <pub-id pub-id-type="pmid">31829902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lokeshwar</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Sprenkle</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer.</article-title>
            <source>Curr Oncol Rep</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-256</page-range>
            <pub-id pub-id-type="pmid">35080739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Neste</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bigley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toll</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delr&#x000e9;e</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.</article-title>
            <source>BMC Urol</source>
            <year>2012</year>
            <month>Jun</month>
            <day>06</day>
            <volume>12</volume>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">22672250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>VAN Criekinge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>VAN Neste</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.</article-title>
            <source>Trans Am Clin Climatol Assoc</source>
            <year>2016</year>
            <volume>127</volume>
            <fpage>313</fpage>
            <page-range>313-327</page-range>
            <pub-id pub-id-type="pmid">28066067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Neste</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.</article-title>
            <source>Prostate</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>76</volume>
            <issue>12</issue>
            <fpage>1078</fpage>
            <page-range>1078-87</page-range>
            <pub-id pub-id-type="pmid">27121847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Van Neste</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delvenne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delr&#x000e9;e</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bigley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>189</volume>
            <issue>3</issue>
            <fpage>1110</fpage>
            <page-range>1110-6</page-range>
            <pub-id pub-id-type="pmid">22999998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Van Neste</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gee</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Troyer</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rieger-Christ</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mangold</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lance</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bigley</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.</article-title>
            <source>J Urol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>192</volume>
            <issue>4</issue>
            <fpage>1081</fpage>
            <page-range>1081-7</page-range>
            <pub-id pub-id-type="pmid">24747657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooperberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Simko</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Djalilvand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanchbury</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Apr</month>
            <day>10</day>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1428</fpage>
            <page-range>1428-34</page-range>
            <pub-id pub-id-type="pmid">23460710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Yousefi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Choeurng</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Buerki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davicioni</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>778</fpage>
            <page-range>778-86</page-range>
            <pub-id pub-id-type="pmid">25466945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Yousefi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davicioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Netto</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Marchionni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fedor</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Glavaris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choeurng</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Buerki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Erho</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Faraj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bezerra</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-65</page-range>
            <pub-id pub-id-type="pmid">26058959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erho</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Crisan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vergara</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Mitra</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ghadessi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buerki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergstralh</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kollmeyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sierocinski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ballman</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Triche</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Klee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Davicioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>e66855</fpage>
            <pub-id pub-id-type="pmid">23826159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yousefi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Choeurng</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Palmer-Aronsten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buerki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davicioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.</article-title>
            <source>Urology</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>90</volume>
            <fpage>148</fpage>
            <page-range>148-52</page-range>
            <pub-id pub-id-type="pmid">26809071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jairath</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Dal Pra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vince</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dess</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Tosoian</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahal</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kishan</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Den</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Salami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mohamad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Cooperberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tward</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Spratt</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.</article-title>
            <source>Eur Urol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>374</fpage>
            <page-range>374-383</page-range>
            <pub-id pub-id-type="pmid">33293078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cullen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsiatis</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Moncur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Knezevic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maddala</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Febbo</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-31</page-range>
            <pub-id pub-id-type="pmid">25465337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cooperberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simko</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Falzarano</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Maddala</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tsiatis</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cherbavaz</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Pelham</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tenggara-Hunter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baehner</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Knezevic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Febbo</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Shak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.</article-title>
            <source>Eur Urol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>550</fpage>
            <page-range>550-60</page-range>
            <pub-id pub-id-type="pmid">24836057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brooks</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crager</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aboushwareb</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality.</article-title>
            <source>JCO Precis Oncol</source>
            <year>2021</year>
            <volume>5</volume>
            <pub-id pub-id-type="pmid">34036236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Covas Moschovas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sandri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dell'Oglio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roof</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sighinolfi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy.</article-title>
            <source>Eur Urol Focus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>418</fpage>
            <page-range>418-424</page-range>
            <pub-id pub-id-type="pmid">33757735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shipitsin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giladi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nifong</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Dunyak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Blume-Jensen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.</article-title>
            <source>Br J Cancer</source>
            <year>2014</year>
            <month>Sep</month>
            <day>09</day>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>1201</fpage>
            <page-range>1201-12</page-range>
            <pub-id pub-id-type="pmid">25032733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blume-Jensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Shipitsin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Putzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nifong</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capela</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coupal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaprelyants</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Giladi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dunyak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Latour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2015</year>
            <month>Jun</month>
            <day>01</day>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>2591</fpage>
            <page-range>2591-600</page-range>
            <pub-id pub-id-type="pmid">25733599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alford</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tewari</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Renzulli</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Use of Biomarkers in Prostate Cancer Screening and Treatment.</article-title>
            <source>Rev Urol</source>
            <year>2017</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-234</page-range>
            <pub-id pub-id-type="pmid">29472826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuzick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>North</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Berney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Beltran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanchbury</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brawer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.</article-title>
            <source>Br J Cancer</source>
            <year>2015</year>
            <month>Jul</month>
            <day>28</day>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-9</page-range>
            <pub-id pub-id-type="pmid">26103570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuzick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brothman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Berney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mesher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Speights</surname>
                <given-names>VO</given-names>
              </name>
              <name>
                <surname>Stankiewicz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Younus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flake</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanchbury</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>S</given-names>
              </name>
              <collab>Transatlantic Prostate Group</collab>
            </person-group>
            <article-title>Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.</article-title>
            <source>Lancet Oncol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-55</page-range>
            <pub-id pub-id-type="pmid">21310658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sommariva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tarricone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lazzeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ricciardi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-15</page-range>
            <pub-id pub-id-type="pmid">25481455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.</article-title>
            <source>Mol Oncol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>22</issue>
            <fpage>4011</fpage>
            <page-range>4011-4022</page-range>
            <pub-id pub-id-type="pmid">36209367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Heyer</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Homologous recombination in DNA repair and DNA damage tolerance.</article-title>
            <source>Cell Res</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-113</page-range>
            <pub-id pub-id-type="pmid">18166982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Microsatellite instability: a review of what the oncologist should know.</article-title>
            <source>Cancer Cell Int</source>
            <year>2020</year>
            <volume>20</volume>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">31956294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas.</article-title>
            <source>PLoS One</source>
            <year>2021</year>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>e0246356</fpage>
            <pub-id pub-id-type="pmid">33524032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms and functions of DNA mismatch repair.</article-title>
            <source>Cell Res</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-98</page-range>
            <pub-id pub-id-type="pmid">18157157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Budczies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kluck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stenzinger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinicrope</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.</article-title>
            <source>Cancer Discov</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1808</fpage>
            <page-range>1808-1825</page-range>
            <pub-id pub-id-type="pmid">33139244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mel&#x000e9;ndez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Van Campenhout</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rorive</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Remmelink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>D'Haene</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Methods of measurement for tumor mutational burden in tumor tissue.</article-title>
            <source>Transl Lung Cancer Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-667</page-range>
            <pub-id pub-id-type="pmid">30505710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abida</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Armenia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Middha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Autio</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Rathkopf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Danila</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Slovin</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Hullings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hechtman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laudone</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wolchok</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Socci</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Sawyers</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solit</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gopalan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.</article-title>
            <source>JAMA Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>471</fpage>
            <page-range>471-478</page-range>
            <pub-id pub-id-type="pmid">30589920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol Focus</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-539</page-range>
            <pub-id pub-id-type="pmid">28753843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobhani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neeli</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pittacolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sirico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Roviello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nesi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>May</month>
            <day>24</day>
            <volume>22</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34073713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;rnberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ylitalo</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Crnalic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antti</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stattin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Widmark</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wikstr&#x000f6;m</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.</article-title>
            <source>PLoS One</source>
            <year>2011</year>
            <month>Apr</month>
            <day>28</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>e19059</fpage>
            <pub-id pub-id-type="pmid">21552559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Louw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jendrisak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bambury</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danila</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marrinucci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dittamore</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.</article-title>
            <source>JAMA Oncol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>1441</fpage>
            <page-range>1441-1449</page-range>
            <pub-id pub-id-type="pmid">27262168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieb</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abdulrahman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weigelt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hauch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gombert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bellut</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goebell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>St&#x000f6;hr</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wullich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wach</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Nov</month>
            <day>18</day>
            <volume>10</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34831445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacheco-Orozco</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Montealegre-P&#x000e1;ez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cayol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Gregorio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frecha</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaca-Paniagua</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perdomo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.</article-title>
            <source>Oncologist</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>e1990</fpage>
            <page-range>e1990-e1995</page-range>
            <pub-id pub-id-type="pmid">32721059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fay</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Antonarakis</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?</article-title>
            <source>Ann Transl Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>Suppl 1</issue>
            <fpage>S7</fpage>
            <pub-id pub-id-type="pmid">31032288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>The Role of CD276 in Cancers.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>654684</fpage>
            <pub-id pub-id-type="pmid">33842369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turiello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morello</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>CD73: A Promising Biomarker in Cancer Patients.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>609931</fpage>
            <pub-id pub-id-type="pmid">33364969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shigemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hadibrata</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Risan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zulfiqqar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soeroharjo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hendri</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Danarto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Heriyanto</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Fujisawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients' survival and responses to androgen deprivation therapies in Indonesian patients cohort.</article-title>
            <source>Prostate Int</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>62</fpage>
            <page-range>62-69</page-range>
            <pub-id pub-id-type="pmid">32647642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyake</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Owari</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tatsumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Oct</month>
            <day>27</day>
            <volume>12</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">33121123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.</article-title>
            <source>Aging (Albany NY)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>06</day>
            <volume>13</volume>
            <issue>13</issue>
            <fpage>17442</fpage>
            <page-range>17442-17461</page-range>
            <pub-id pub-id-type="pmid">34229299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hempel Sullivan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heaphy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kulac</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cuka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>De Marzo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Joshu</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Sfanos</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>668</fpage>
            <page-range>668-675</page-range>
            <pub-id pub-id-type="pmid">31932412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pittoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The dark side of mast cell-targeted therapy in prostate cancer.</article-title>
            <source>Cancer Res</source>
            <year>2012</year>
            <month>Feb</month>
            <day>15</day>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>831</fpage>
            <page-range>831-5</page-range>
            <pub-id pub-id-type="pmid">22307838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamaspishvili</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>De Marzo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications of PTEN loss in prostate cancer.</article-title>
            <source>Nat Rev Urol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>222</fpage>
            <page-range>222-234</page-range>
            <pub-id pub-id-type="pmid">29460925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dillinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sheibani-Tezerji</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pulverer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stelzer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hassler</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Scheibelreiter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Malla</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Kuroll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Domazet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Redl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ely</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brezina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tiefenbacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rebhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grubm&#x000fc;ller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mitterhauser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinhaeusel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeitlinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gsur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Kenner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.</article-title>
            <source>Mol Cancer</source>
            <year>2022</year>
            <month>Jan</month>
            <day>03</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">34980142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rochow</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weickmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ralla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stephan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elezkurtaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fendler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Oct</month>
            <day>22</day>
            <volume>21</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">33105568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144431.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Fresh Frozen Tissue With Formalin-Fixed Paraffin-Embedded Tissue for Mutation Analysis Using a Multi-Gene Panel in Patients With Colorectal Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>310</fpage>
            <pub-id pub-id-type="pmid">32232001</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
